Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05230537 · ClinicalTrials.gov registry record · Phase 2
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
A Phase 2 study of Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT05230537: Active Phase 2 study of Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals.
NCT05230537 is a Phase 2 study of Age-related Macular Degeneration that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 170 participants, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05230537, a Phase 2 study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Primary Outcome
OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Iptacopan (LNP023)
Study Locations (20)
California
- Retina Consultants of Orange County - Fullerton
- Salehi Retina Institute - Huntington Beach
- Martel Eye Medical Group - Rancho Cordova
- Retinal Consultants Medical Group Inc - Sacramento
- California Retina Consultants - Santa Barbara
Florida
- Advanced Research LLC - Deerfield Beach
- Retina Center Of South Florida - Delray Beach
- Retina Vitreous Associates of Florida - St. Petersburg
Texas
- Austin Research Center for Retina - Austin
- Retina Consultants TX Rsrch Ctr - Bellaire
- Retina Foundation - Dallas
Colorado
- Southwest Retina Research Center - Durango
Indiana
- Midwest Eye Institute - Indianapolis
Louisiana
- Retina Associates New Orleans - New Orleans
Maryland
- Retina Care Center - Baltimore
Massachusetts
- Opthamalic Consultants of Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2026-10-02 |
| Phase | Phase 2 |
What the registry record for NCT05230537 still lists
NCT05230537 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05230537 names 20 study sites across 12 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05230537 about?
NCT05230537 is a clinical study titled "A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration". The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
What is the current status of trial NCT05230537?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2022-02-17. Estimated completion is 2026-10-02.
What conditions does trial NCT05230537 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT05230537?
The interventions under investigation include: Placebo (DRUG), Iptacopan (LNP023) (DRUG).
Who is sponsoring clinical trial NCT05230537?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05230537 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05230537's enrollment target sits among peer trials
170 19th of 74 higher than 56 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of RQC for AMD
COMPLETED · Phase 2
-
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
-
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI